BOILLHEALTHCARE receives additional resumption guidance
BOILLHEALTHCARE received additional resumption guidance from the Stock Exchange, requiring the company to complete an independent forensic investigation, demonstrate that there are no significant doubts about the integrity and competence of the management, and conduct an independent internal control review by January 28, 2025, to ensure compliance with listing rules
According to the announcement from BOILLHEALTHCARE (01246), on January 28, 2025, the Stock Exchange notified the company that it must comply with the following further resumption guidance in order to resume trading:
(i) Conduct an independent forensic investigation into matters related to unauthorized guarantees, non-controlling equity loans A, non-controlling equity loans B, and sale transactions to identify any unauthorized loans/guarantees, assess the impact on the company's business operations and financial condition, disclose the investigation results, and take appropriate remedial measures;
(ii) Demonstrate that there are no reasonable doubts regarding the integrity, capability, and/or character of individuals who have significant influence over the group's management and/or the company's management and operations that may pose risks to investors and damage market confidence; and
(iii) Conduct an independent internal control review to demonstrate that the company has implemented adequate internal controls and procedures to comply with the Listing Rules
